Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NANP | Q8TBE9 | 2/20 | 0.40 |
| ▸ | NEU1 | Q99519 | 8/20 | 0.39 |
| ▸ | NEU2 | Q9Y3R4 | 7/20 | 0.39 |
| ▸ | NEU3 | Q9UQ49 | 4/20 | 0.39 |
| ▸ | NEU4 | Q8WWR8 | 4/20 | 0.39 |
| ▸ | CD22 | P20273 | 4/20 | 0.37 |
| ▸ | MAG | P20916 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23640226 | 0.89 | L3MBTL1 (0.44) | L3MBTL1NANPNEU1NEU2NEU3 | |
| SCHEMBL26774774 | 0.86 | NEU1 (0.52) | L3MBTL1NANPNEU1NEU2NEU3 | |
| SCHEMBL20122292 | 0.86 | NANP (0.53) | L3MBTL1NANPNEU1NEU2NEU3 | |
| SCHEMBL23640384 | 0.86 | NANP (0.53) | L3MBTL1NANPNEU1NEU2NEU3 | |
| SCHEMBL25518923 | 0.86 | NANP (0.53) | L3MBTL1NANPNEU1NEU2NEU3 | |
| SCHEMBL26774733 | 0.82 | NEU2 (0.54) | L3MBTL1NANPNEU1NEU2NEU3 | |
| SCHEMBL26774832 | 0.81 | NANP (0.50) | NANPNEU1NEU2NEU3NEU4 | |
| SCHEMBL23591471 | 0.78 | L3MBTL1 (0.50) | L3MBTL1NANPNEU1NEU2NEU3 | |
| SCHEMBL23640230 | 0.78 | L3MBTL1 (0.50) | L3MBTL1NANPNEU1NEU2NEU3 | |
| SCHEMBL26774745 | 0.78 | NANP (0.53) | L3MBTL1NANPNEU1NEU2NEU3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372528-A1 | GLYCOCONJUGATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372528-A1 | GLYCOCONJUGATES | CD22, SIGLEC7, CD47 | L3MBTL1 1555/4885NANP 511/4885NEU1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.